- BioHarvest Sciences Inc. (BHSC) has reached an important milestone in its development program of additional Nutraceuticals
- The olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low-calorie count per serving
- BioHarvest’s olive cells-based product will contain verbascoside, an ingredient with potent activity from the olive tree
- It is the first and only industrial-scale plant cell technology capable of producing active plant ingredients without the necessity to grow the plant itself
- BioHarvest Sciences Inc. is up 3.51 percent and is trading at C$0.59 at 12:35 pm EST
BioHarvest Sciences Inc. (BHSC) has reached an important milestone in its Nutraceuticals development program.
The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside.
These compounds are the primary polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil.
Notably, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low-calorie count per serving.
The polyphenols found in olives have demonstrated positive effects on learning and reducing memory deficits found in ageing.
These polyphenols also impact gut microbial balance by promoting the growth of bacteria, influencing lipid metabolism and inhibition of pathogenic bacteria, and increasing bone density.
BioHarvest’s olive cells-based product will contain verbascoside, an ingredient with potent activity from the olive tree. Most olive extracts are based only on hydroxytyrosol.
“We are very proud to have achieved this milestone,” said Dr. Yochi Hagay, CTO of the Company and added, “Our Nutraceuticals development program includes new products with active ingredients that have scientifically demonstrated a positive impact on a person’s wellbeing.”
“Our olive-based Nutraceutical contains a matrix of active components with special antioxidant activities and unlike other products (which use the typical solvent extraction technique), is based on our proprietary BioFarming technology,” said Ilan Sobel, the CEO of BioHarvest Sciences.
“We expect to commercialize this olive-based product alongside our current flagship VINIA® product in 2022 to create a portfolio of superfruits and Nutraceuticals with unprecedented benefits and sales growth potential in the C$53 Billion dietary supplement market in the US (2020 Persistence Market Research),” added Sobel.
Based in Vancouver, BC, BioHarvest is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology.
It is the first and only industrial-scale plant cell technology capable of producing active plant ingredients without growing the plant itself.
BioHarvest Sciences Inc. is up 3.51 percent and is trading at C$0.59 at 12:35 pm EST.
